ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and rheumatoid arthritis"

  • Abstract Number: 2711 • 2015 ACR/ARHP Annual Meeting

    The Lung Microbiome in Rheumatoid Arthritis and Associated Local/Systemic Autoimmunity

    Jose U. Scher1, Vijay Joshua2, Carles Ubeda3, Alejandro Artacho3, Leopoldo Segal4 and Anca I Catrina5, 1Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Cmm L8:04, Karolinska Institutet, Stockholm, Sweden, 3Institute for Research in Public Health, Valencia, Spain, 4Medicine, Pulmonay Division, NYU School of Medicine, New York City, NY, 5Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disorder in which several genetic and environmental factors play a role. Recent data suggest that the gut…
  • Abstract Number: 2825 • 2014 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel®), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA)

    Sang-Cheol Bae1, Jinseok Kim2, Jung-Yoon Choe3, Won Park4, So-Ra Lee5, Yongho Ahn6 and Yunjeong Seo7, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Internal Medicine, Jeju National University, Jeju, Korea, South Korea, 3Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, 4Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, 5Clinical Development/Regulatory Affairs, Hanwha Chemical, Seoul, South Korea, 6R&D Center, Hanwha Chemical, Daejeon, South Korea, 7Clinical Development, Hanwha Chemical, Seoul, South Korea

    Background/Purpose Etanercept is a recombinant fusion protein that blocks TNF activity. HD203 is a biosimilar of etanercept. In a double-blind, randomized study in healthy volunteers,…
  • Abstract Number: 336 • 2014 ACR/ARHP Annual Meeting

    The Additive Inflammatory in Vivo and in Vitro Effects of Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis Underscore the Therapeutic Rationale for blockade of Their Common Receptor Subunit

    M.R. Hillen1,2, S.A.Y. Hartgring1,2, T.R.D.J. Radstake2,3, C.E. Hack1,2, F.P.J.G. Lafeber1 and J.a.G. van Roon1,2, 1Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, 2Laboratory for Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 3Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose Interleukin (IL)-7 and thymic stromal lymphopoietin (TSLP) are cytokines that signal through the IL-7Ra subunit and play proinflammatory roles in experimental arthritis and rheumatoid…
  • Abstract Number: 2236 • 2013 ACR/ARHP Annual Meeting

    Articular Inflammation Is Protected By Fat-1 During The Acute Phase Of Arthritis In Mice

    Sang-Il Lee1, Yun-Hong Cheon2, Ji-Min Kim3 and Won Seok Lee2, 1Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, 2Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea

    Background/Purpose: Omega-3 polyunsaturated fatty acids (n-3 PUFA) are well known to exert anti-inflammatory effects. The Fat-1 transgenic (Fat-1 TG) mice are capable of producing n-3…
  • Abstract Number: 2112 • 2013 ACR/ARHP Annual Meeting

    Hip and Knee Arthroplasty In Patients With Rheumatoid Arthritis: Results From The Australian Orthopaedic Association National Joint Replacement Registry: 2003 To 2011

    Andrew Lim1, Stephen Graves2, Yen Liu2, Lionel Schachna1 and Russell R. Buchanan1, 1Rheumatology, Austin Health, Melbourne, Australia, 2Australian Orthopaedic Association National Joint Replacement Registry, Adelaide, Australia

    Background/Purpose: Total Joint Replacement in rheumatoid arthritis (RA) patients is a marker of disease severity. Whilst the rate of total hip (THA) and total knee…
  • Abstract Number: 1439 • 2013 ACR/ARHP Annual Meeting

    Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis

    Charles Inderjeeth1, Andrew Redfern1, Michael Huang2, Yun Hardiman2, Theresa Grant2, Lawrence C. Fritz2, David Fuller3, David Haughey4 and Mark C. Totoritis2, 1Linear Clinical Research Ltd, Perth, Australia, 2Santarus, Inc., San Diego, CA, 3INC Research, Inc., New South Wales, Australia, 4ICON Development Solutions, Whitesboro, NY

    Background/Purpose: Very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule expressed on activated lymphocytes and monocytes/macrophages, binds extracellular matrix molecules and facilitates migration, proliferation,…
  • Abstract Number: 1387 • 2013 ACR/ARHP Annual Meeting

    Reversing Vascular Dysfunction In Rheumatoid Arthritis: Peroxisome Proliferator-Activated Receptor Gamma Agonist Therapy Improves Augmentation Index But Not Endothelial Function

    Michelle J. Ormseth1, Aihua Bian2, Annette M. Oeser2, Andrew Cunningham2, Ayumi Shintani2, S. Bobo Tanner3 and C. Michael Stein4, 1Rheumatology, Vanderbilt Medical Center, Nashville, TN, 2Vanderbilt Medical Center, Nashville, TN, 3Div of Rheumatology & Allergy, Vanderbilt Medical Center, Nashville, TN, 4School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN

    Background/Purpose: Rheumatoid arthritis (RA) is associated with insulin resistance and increased cardiovascular (CV) risk. Impaired vascular function, including arterial stiffness and endothelial dysfunction, is associated…
  • Abstract Number: 955 • 2013 ACR/ARHP Annual Meeting

    Myeloid Deletion Of SIRT1 Aggravates Serum Transfer Arthritis But Ameliorate Collagen-Induced Arthritis

    Sang-Il Lee1, Yun-Hong Cheon2, Won Seok Lee2 and Ji-Min Kim3, 1Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, 2Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea

    Background/Purpose: SIRT1 plays a pivotal role in regulating the inflammatory response. Thus, we assessed the role of SIRT1 in K/BxN serum transfer arthritis as a…
  • Abstract Number: 2489 • 2012 ACR/ARHP Annual Meeting

    Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634

    Frédéric Vanhoutte1, Minodora Mazur2, Annegret Van der Aa1, Piet Wigerinck1 and Gerben van 't Klooster1, 1Galapagos NV, Mechelen, Belgium, 2Rheumatology, State Medical and Pharmaceutical University "Nicolae Testemitanu", Chisinau, Moldova

    Background/Purpose: Janus kinases (JAKs) are critical components in signaling pathways for a number of cytokines and growth factors, including those involved in the disease process…
  • Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting

    ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats

    Shunji Yamazaki1, Masamichi Inami1, Misato Ito1, Yasutomo Fujii1, Kaori Hanaoka1, Kaoru Yamagami1, Kenji Okuma1, Yoshiaki Morita1, Shohei Shirakami2, Takayuki Inoue2, Susumu Miyata3 and Yasuyuki Higashi1, 1Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, 2Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, 3Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan

    Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…
  • Abstract Number: 1831 • 2012 ACR/ARHP Annual Meeting

    Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database

    Eiichi Tanaka1, Eisuke Inoue2, Daisuke Hoshi3, Akiko Kobayashi2, Naoki Sugimoto2, Kumi Shidara2, Eri Sato3, Yasushi Inoue3, Yohei Seto2, Ayako Nakajima4, Shigeki Momohara3, Atsuo Taniguchi2 and Hisashi Yamanaka3, 1Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable…
  • Abstract Number: 1692 • 2012 ACR/ARHP Annual Meeting

    Lung Microbiome Differs in Subjects with Rheumatoid Arthritis-Related Autoimmunity without Inflammatory Arthritis Compared to Healthy Seronegative Controls

    M. Kristen Demoruelle1, Jill M. Norris2, V. Michael Holers3, Kevin D. Deane1 and J. Kirk Harris4, 1Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2Epidemiology, Colorado School of Public Health, Aurora, CO, 3Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose:   Emerging data suggest that microorganisms and mucosal inflammation may play a role in the etiology of rheumatoid arthritis (RA). Furthermore, our published findings…
  • Abstract Number: 1637 • 2012 ACR/ARHP Annual Meeting

    A Novel Peptide Inhibiting the Binding Between C1q and Immunoglobulin Ameliorates Joint Destruction in Rats with Collagen-Induced Arthritis

    Yu Moriguichi and Tetsuya Tomita, Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan

    Background/Purpose: C1q is the major subcomponent of the first component of complement protein. The activation of the complement is triggered by binding of C1q to…
  • Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting

    First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis

    Stanislav Ignatenko1, Birte K. Skrumsager2, Adam Steensberg3 and Ulrik Mouritzen3, 1Charité Research Organization GmbH, Berlin, Germany, 2Clinical Pharmacology Biopharm, Novo Nordisk A/S, Copenhagen, Denmark, 3Medical & Science, Inflammation, Novo Nordisk A/S, Copenhagen, Denmark

    Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…
  • Abstract Number: 1184 • 2012 ACR/ARHP Annual Meeting

    Negative Association Between Testosterone Levels and Risk of Future Rheumatoid Factor Negative Rheumatoid Arthritis in Men

    Mitra Pikwer1, Aleksander Giwercman2, Ulf Bergström1, Jan-Åke Nilsson3, Lennart T.H. Jacobsson3 and Carl Turesson3, 1Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Reproductive Medicine Centre, Skåne University Hospital, Malmö, Sweden, 3Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease with female predominance. Sex hormones have been suggested to play a part in the pathogenesis. We have previously…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology